What to Expect from a Libido Medication Consultation

In an June editorial in the Journal of the American Medical Association, three members of the FDA’s June advisory committee wrote of Even the Score: “Although flibanserin is not the first product to be supported by a consumer advocacy group [that is] in turn supported by pharmaceutical manufacturers, claims of gender bias regarding the FDA’s regulation have been particularly noteworthy, as have the extent of advocacy efforts.” But there’s another answer, too: Between the two rejections and the approval, the benchmark for success has changed. A highlights-only timeline of the drug’s rocky history looks like this: Flibanserin was originally developed as an antidepressant.

HOW TO GET YOUR PRESCRIPTION

In an June editorial in the Journal of the American Medical Association, three members of the FDA’s June advisory committee wrote of Even the Score: “Although flibanserin is not the first product to be supported by a consumer advocacy group [that is] in turn supported by pharmaceutical manufacturers, claims of gender bias regarding the FDA’s regulation have been particularly noteworthy, as have the extent of advocacy efforts.” But there’s another answer, too: Between the two rejections and the approval, the benchmark for success has changed. A highlights-only timeline of the drug’s rocky history looks like this: Flibanserin was originally developed as an antidepressant. After initial trials found it to be ineffective, it was redirected as a remedy for low female desire. The pharmaceutical company Boehringer Ingelheim submitted the drug for approval in 2010, though the agency rejected the application, noting that it didn’t seem to work very well for its new purpose, either. Sprout acquired the drug in 2011 and saw another rejection in 2013; this time, the FDA asked for additional safety studies and called for an advisory committee to investigate whether the risks outweighed the modest benefits.

Effects on sexual dysfunction

Boehringer Ingelheim’s first two trials, submitted as part of the application the FDA rejected in 2010, had asked participants to keep a daily digital diary, reporting both the number of “satisfying sexual events” and the highest level of sexual desire they experienced each day. These measures were the study’s primary endpoints, or the main questions a drug trial is designed to answer. Of the two, only the number of satisfying sexual experiences slightly increased with the use of flibanserin; the pill failed to make any meaningful difference on self-reported levels of desire. Put another way, people were having more sex—more good sex, even—but flibanserin wasn’t doing what it was supposed to do: make people want sex more in the first place. But in a move that would later become key to flibanserin’s approval, the studies also had a secondary endpoint: how the women scored on the Female Sexual Function Index (FSFI), a tool that assigns respondents a sexual-function score based on their sexual activity over the month leading up to the survey.

What do females use instead of Viagra?

Unlike the digital diaries, the FSFI asked participants to recall desire from the past four weeks, rather than the past day. Also unlike with the digital diaries, this measure showed a difference between flibanserin and placebos. When Sprout took over the development of flibanserin from BI in 2011, it conducted one more efficacy study of its own, but reshuffled the criteria. The new trial kept the number of satisfying sexual experiences as one primary endpoint, but this time around, participants weren’t asked to record their daily levels of desire; instead, the study used the FSFI—which had previously shown favorable results—as its other main measure. Meanwhile, outside of the FDA, Sprout, and Even the Score, a third thing has changed: Hypoactive Sexual Desire Disorder (HSDD), the condition that flibanserin was developed to treat, is no longer listed by the American Psychiatric Association as its own disorder. After initial trials found it to be ineffective, it was redirected as a remedy for low female desire. The pharmaceutical company Boehringer Ingelheim submitted the drug for approval in 2010, though the agency rejected the application, noting that it didn’t seem to work very well for its new purpose, either. Sprout acquired the drug in 2011 and saw another rejection in 2013; this time, the FDA asked for additional safety studies and called for an advisory committee to investigate whether the risks outweighed the modest benefits.

• Vaginal moisturizers (e.g., Replens) provide long-lasting relief from dryness.
• Vaginal lubricants (e.g., Sylk, YES) reduce friction and discomfort during intercourse.
• Topical estrogen creams (e.g., Vagifem) locally treat vaginal atrophy and dryness.
• Pelvic floor physical therapy can improve muscle tone and blood flow to the pelvis.
• Sex therapy focuses on improving intimacy and communication with a partner.
• Mindfulness and sensate focus exercises can help reduce performance anxiety.
• Devices like the Eros-Clitoral Therapy Device use gentle suction to increase blood flow.

Boehringer Ingelheim’s first two trials, submitted as part of the application the FDA rejected in 2010, had asked participants to keep a daily digital diary, reporting both the number of “satisfying sexual events” and the highest level of sexual desire they experienced each day. These measures were the study’s primary endpoints, or the main questions a drug trial is designed to answer. Of the two, only the number of satisfying sexual experiences slightly increased with the use of flibanserin; the pill failed to make any meaningful difference on self-reported levels of desire. Put another way, people were having more sex—more good sex, even—but flibanserin wasn’t doing what it was supposed to do: make people want sex more in the first place. But in a move that would later become key to flibanserin’s approval, the studies also had a secondary endpoint: how the women scored on the Female Sexual Function Index (FSFI), a tool that assigns respondents a sexual-function score based on their sexual activity over the month leading up to the survey. Unlike the digital diaries, the FSFI asked participants to recall desire from the past four weeks, rather than the past day. Also unlike with the digital diaries, this measure showed a difference between flibanserin and placebos. When Sprout took over the development of flibanserin from BI in 2011, it conducted one more efficacy study of its own, but reshuffled the criteria. The new trial kept the number of satisfying sexual experiences as one primary endpoint, but this time around, participants weren’t asked to record their daily levels of desire; instead, the study used the FSFI—which had previously shown favorable results—as its other main measure. Meanwhile, outside of the FDA, Sprout, and Even the Score, a third thing has changed: Hypoactive Sexual Desire Disorder (HSDD), the condition that flibanserin was developed to treat, is no longer listed by the American Psychiatric Association as its own disorder. At the time that Spout acquired flibanersin, the most recent edition of the DSM was the DSM-IV, which drew a distinction between problems with female desire and problems with arousal. HSDD was its own entry; separately, Female Sexual Arousal Disorder was defined as “persistent or recurrent inability to attain, or to maintain until completion of the sexual activity, an adequate lubrication swelling response of sexual excitement.” But in the DSM-V, published in 2013, the two were combined into one condition, “Female Sexual Interest/Arousal Disorder.” “Research suggests that sexual response is not always a linear, uniform process,” the APA wrote in an explanation of the changes, “and that the distinction between certain phases (e.g., desire and arousal) may be artificial”— a change that complicates the already-complicated arguments for and against the little pink pill. Such therapies, dubbed ‘female Viagra' by the media, may help treat female sexual arousal disorder (FSAD), claimed to affect up to 40% of women. In a series of experiment on rabbits, researchers from Pfizer showed that genital blood flow was increased by the experimental drug UK-414, 495, a neutral endopeptidase. Reductions in genital blood circulation have 50mg viagra been proposed as a cause of FSAD.

Writing in the British Journal of Pharmacology the researchers concluded that neutral endopeptidases ‘may restore sexual arousal in women adversely affected by FSAD'. Lead researcher Chris Wayman commented: ‘While the particular chemical compound studied in this research did not prove appropriate for further development, the implications of the research could lead to the development of a product in future, although Pfizer has no current plans to develop medicines for FSAD'. There’s a new wonder drug in town. Addyi has been hailed as the “female Viagra,” a wonder drug that could do for unsatisfied women what Viagra did for their horny middle-aged boyfriends. For several years, its makers have fought a long and controversial campaign to get FDA approval for the drug, and the FDA has rejected it on the grounds that it doesn’t do enough to justify accepting the side effects. Then a PR campaign was launched, the FDA was put under intense pressure by feminist activists accusing them of patronizing sexism, and the drug was finally approved. It goes on sale in October; but the trouble is, it probably shouldn’t.

HERE IS WHAT SHE SAYS...

On Broadly: What It Feels Like to Take the Newly Approved ‘Female Viagra’ Let’s get past this “female Viagra” bullshit before we go any further. It couldn’t be less like Viagra if it were trying to evade an email spam filter, and comparing them is doubly confusing because most people don’t actually know much about Viagra to begin with.

• Flibanserin works on neurotransmitters in the brain, increasing dopamine and noradrenaline.
• It simultaneously decreases serotonin activity, which is thought to inhibit sexual desire.
• Bremelanotide is a melanocortin receptor agonist that acts on pathways in the brain.
• Ospemifene is a Selective Estrogen Receptor Modulator (SERM) with estrogen-like effects.
• Testosterone is thought to play a key role in libido for both men and women.
• Topical estrogens work by replenishing thinning vaginal tissues.
• Understanding the mechanism helps in choosing the right treatment for the cause.

When you take Viagra nothing actually happens; or at least nothing noticeable. Contrary to popular myth it doesn’t suddenly increase your sex drive or make you instantly horny. It’s not for increasing your libido. What it does is make it easier to get and maintain an erection once you’re aroused, something that can be achieved pretty simply with a single dose. It’s basically just hydraulics—a penis is a big dangling sack of blood, swinging around like an uncooked black pudding, and Viagra helps keep that sack pumped up. Addyi—or flibanserin, to use its non-commercial name—is radically different.

We got busy with a full clinical study.

Contrary to popular myth it doesn’t suddenly increase your sex drive or make you instantly horny. It’s not for increasing your libido. What it does is make it easier to get and maintain an erection once you’re aroused, something that can be achieved pretty simply with a single dose. It’s basically just hydraulics—a penis is a big dangling sack of blood, swinging around like an uncooked black pudding, and Viagra helps keep that sack pumped up. Addyi—or flibanserin, to use its non-commercial name—is radically different.

What happens when females take Viagra?

It started out in the 1990s as an experimental antidepressant, and works on the brain rather than the body, altering the balance of neurotransmitters like dopamine and serotonin in an effort to trigger parts of the brain involved in “sexual desire.” The effects are subtle—so subtle that you’d be forgiven for asking whether they really exist. In the trials generic viagra sildenafil citrate 50 mg the FDA looked at, the average woman started out reporting 2.8 “satisfying sexual events” per month. For women given a placebo, that went up to 3.7, and for women on Addyi it was 4.5 times per month. In other words, women who took Addyi had an average of 0.8 more “satisfying sexual events” in a month than women who just took a sugar pill. That’s not much better than a rounding error.

What is FSAD?

Getting your extra eight-tenths of an orgasm takes a lot of work, too. Unlike Viagra, this isn’t a question of just popping a pill, the lying back and thinking of England—you have to take Addyi for a month, during which time you can’t drink alcohol. Amazingly, the research that looked at what happens when you mix alcohol and Addyi—bad things—was done almost entirely on men. Ironically, the drug can also react badly with some hormonal contraceptives, and like many medications it has a raft of side effects—fainting, low blood pressure, nausea, sedation, and in rare cases potential liver damage. Seeking a woman’s opinion, I turned to my friend Jennifer. It started out in the 1990s as an experimental antidepressant, and works on the brain rather than the body, altering the balance of neurotransmitters like dopamine and serotonin in an effort to trigger parts of the brain involved in “sexual desire.” The effects are subtle—so subtle that you’d be forgiven for asking whether they really exist. In the trials generic viagra sildenafil citrate 50 mg the FDA looked at, the average woman started out reporting 2.8 “satisfying sexual events” per month. For women given a placebo, that went up to 3.7, and for women on Addyi it was 4.5 times per month. In other words, women who took Addyi had an average of 0.8 more “satisfying sexual events” in a month than women who just took a sugar pill. That’s not much better than a rounding error. Getting your extra eight-tenths of an orgasm takes a lot of work, too. Unlike Viagra, this isn’t a question of just popping a pill, the lying back and thinking of England—you have to take Addyi for a month, during which time you can’t drink alcohol.

Interested, but not quite ready?

Amazingly, the research that looked at what happens when you mix alcohol and Addyi—bad things—was done almost entirely on men.

Ironically, the drug can also react badly with some hormonal contraceptives, and like many medications it has a raft of side effects—fainting, low blood pressure, nausea, sedation, and in rare cases potential liver damage. Seeking a woman’s opinion, I turned to my friend Jennifer. A veritable expert on the ins and outs of orgasms, she gave me the following assessment: “If I’m taking a tablet every day that means I can’t drink, in favor of orgasms, I want at least one or two orgasms a day.

What women are saying

A veritable expert on the ins and outs of orgasms, she gave me the following assessment: “If I’m taking a tablet every day that means I can’t drink, in favor of orgasms, I want at least one or two orgasms a day. If it comes with risks of liver damage and syncope, I want five or six. And if I can’t take the contraceptive pill, I want it to come with free condoms.” These benefits weren’t compared with other interventions, either. Addyi might—just—work better than a placebo, but there are many other ways for women to improve their sexual experiences without resorting to a pill that’s loaded with side effects: sex toys, a better partner, addressing any health or psychological issues, or just installing a new shower head. This drug isn’t for just any woman, though.

A note about sex and gender

It’s aimed at women suffering from a newly described condition known as Hypoactive Sexual Desire Disorder (HSDD). HSDD is diagnosed when you have very low sexual desire that causes serious distress and/or relationship problems, but isn’t accounted for by some other medical problem. HSDD is a controversial disorder, with a whole bunch of problems that lead some people to question whether it’s really a “disorder” at all. The first is what you mean by “low sexual desire.” If you tell someone her sexuality is abnormal, you’re making some kind of judgment about what “normal” is supposed to be, and really that’s a cultural thing. It’s the same issue psychologists had with homosexuality when it was still classified as a medical disorder illness—society has a long and bad history of saying anything that doesn’t fit a very narrow definition of sexuality is a mental illness.

Increased genital blood flow

Even if you believe it’s a real disorder, the chances are many women will be misdiagnosed, or coerced into getting the drugs by pushy partners. In the best-case scenario, you’re empowering women struggling with a legitimate condition to have more sexual pleasure. In the worst case, you’re taking healthy women who don’t meet society’s expectations—or more likely the expectations of their men—and drugging them to be more compliant. If it comes with risks of liver damage and syncope, I want five or six. And if I can’t take the contraceptive pill, I want it to come with free condoms.” These benefits weren’t compared with other interventions, either. Addyi might—just—work better than a placebo, but there are many other ways for women to improve their sexual experiences without resorting to a pill that’s loaded with side effects: sex toys, a better partner, addressing any health or psychological issues, or just installing a new shower head. This drug isn’t for just any woman, though.

If you're tired of uncertain quality and unproven options, you're not alone.

It’s aimed at women suffering from a newly described condition known as Hypoactive Sexual Desire Disorder (HSDD). HSDD is diagnosed when you have very low sexual desire that causes serious distress and/or relationship problems, but isn’t accounted for by some other medical problem.

Real Science. Real Results.

At the time that Spout acquired flibanersin, the most recent edition of the DSM was the DSM-IV, which drew a distinction between problems with female desire and problems with arousal. HSDD was its own entry; separately, Female Sexual Arousal Disorder was defined as “persistent or recurrent inability to attain, or to maintain until completion of the sexual activity, an adequate lubrication swelling response of sexual excitement.” But in the DSM-V, published in 2013, the two were combined into one condition, “Female Sexual Interest/Arousal Disorder.” “Research suggests that sexual response is not always a linear, uniform process,” the APA wrote in an explanation of the changes, “and that the distinction between certain phases (e.g., desire and arousal) may be artificial”— a change that complicates the already-complicated arguments for and against the little pink pill. Such therapies, dubbed ‘female Viagra' by the media, may help treat female sexual arousal disorder (FSAD), claimed to affect up to 40% of women. In a series of experiment on rabbits, researchers from Pfizer showed that genital blood flow was increased by the experimental drug UK-414, 495, a neutral endopeptidase. Reductions in genital blood circulation have 50mg viagra been proposed as a cause of FSAD.

Addyi (filbanserin)

Writing in the British Journal of Pharmacology the researchers concluded that neutral endopeptidases ‘may restore sexual arousal in women adversely affected by FSAD'. Lead researcher Chris Wayman commented: ‘While the particular chemical compound studied in this research did not prove appropriate for further development, the implications of the research could lead to the development of a product in future, although Pfizer has no current plans to develop medicines for FSAD'. There’s a new wonder drug in town. Addyi has been hailed as the “female Viagra,” a wonder drug that could do for unsatisfied women what Viagra did for their horny middle-aged boyfriends. For several years, its makers have fought a long and controversial campaign to get FDA approval for the drug, and the FDA has rejected it on the grounds that it doesn’t do enough to justify accepting the side effects.

11 natural aphrodisiacs for females

Then a PR campaign was launched, the FDA was put under intense pressure by feminist activists accusing them of patronizing sexism, and the drug was finally approved. It goes on sale in October; but the trouble is, it probably shouldn’t. On Broadly: What It Feels Like to Take the Newly Approved ‘Female Viagra’ Let’s get past this “female Viagra” bullshit before we go any further. It couldn’t be less like Viagra if it were trying to evade an email spam filter, and comparing them is doubly confusing because most people don’t actually know much about Viagra to begin with. When you take Viagra nothing actually happens; or at least nothing noticeable. HSDD is a controversial disorder, with a whole bunch of problems that lead some people to question whether it’s really a “disorder” at all. The first is what you mean by “low sexual desire.” If you tell someone her sexuality is abnormal, you’re making some kind of judgment about what “normal” is supposed to be, and really that’s a cultural thing. It’s the same issue psychologists had with homosexuality when it was still classified as a medical disorder illness—society has a long and bad history of saying anything that doesn’t fit a very narrow definition of sexuality is a mental illness. Even if you believe it’s a real disorder, the chances are many women will be misdiagnosed, or coerced into getting the drugs by pushy partners. In the best-case scenario, you’re empowering women struggling with a legitimate condition to have more sexual pleasure. In the worst case, you’re taking healthy women who don’t meet society’s expectations—or more likely the expectations of their men—and drugging them to be more compliant.